Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.
2.

Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.

John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, Mallal SA.

AIDS. 2001 Apr 13;15(6):717-23.

PMID:
11371686
3.
4.
5.

Use of Tris-hydroxymethyl aminomethane in severe lactic acidosis due to highly active antiretroviral therapy: a case report.

Marfo K, Garala M, Kvetan V, Gasperino J.

J Clin Pharm Ther. 2009 Feb;34(1):119-23. doi: 10.1111/j.1365-2710.2008.00977.x.

PMID:
19125910
6.

Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases.

ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K.

Int J STD AIDS. 2000 Sep;11(9):611-6.

PMID:
10997508
7.

Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment.

Vrouenraets SM, Treskes M, Regez RM, Troost N, Smulders YM, Weigel HM, Frissen PH, Brinkman K.

Antivir Ther. 2002 Dec;7(4):239-44.

PMID:
12553477
8.

Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan.

Sheng WH, Hsieh SM, Lee SC, Chen MY, Wang JT, Hung CC, Chang SC.

Int J STD AIDS. 2004 Apr;15(4):249-53.

PMID:
15075019
9.

Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy.

Calza L, Manfredi R, Chiodo F.

Clin Nutr. 2005 Feb;24(1):5-15. Review.

PMID:
15681097
10.

[Lactic acidosis in HIV-patients--diagnosis and treatment].

Walker UA.

MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:65-7. German.

PMID:
15373054
11.

Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors.

Claessens YE, Chiche JD, Mira JP, Cariou A.

Crit Care. 2003 Jun;7(3):226-32. Epub 2003 Feb 28. Review.

12.

Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy.

Haugaard SB, Andersen O, Pedersen SB, Dela F, Richelsen B, Nielsen JO, Madsbad S, Iversen J.

J Med Virol. 2005 Sep;77(1):29-38.

PMID:
16032748
14.

Evidence for mitochondrial toxicity: lactic acidosis as proof of concept.

Brinkman K.

J HIV Ther. 2001 Mar;6(1):13-6. Review. No abstract available.

PMID:
11501196
15.

The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.

Sternfeld T, Schmid M, Tischleder A, Mudra S, Schlamp A, Kost BP, Gruber R, Youle M, Bogner JR, Goebel FD.

Antivir Ther. 2007;12(5):769-78.

PMID:
17713160
16.
17.

Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antiretroviral therapy.

Tolomeo M, Mancuso S, Todaro M, Stassi G, Catalano M, Arista S, Cannizzo G, Barbusca E, Abbadessa V.

J Clin Pathol. 2003 Feb;56(2):147-51.

18.

Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.

Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-Jărvinen H, Back DJ, Pirmohamed M, Gazzard BG, Walker UA, Moyle GJ.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):565-72.

PMID:
16284533
19.

Mitochondrial toxicity and HIV therapy.

White AJ.

Sex Transm Infect. 2001 Jun;77(3):158-73. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk